Jon Reichert, an S&P credit analyst, said in a news release the decreased outlook signals the rating agency’s expectation of weakened operating earnings. S&P expects Highmark’s return on revenue to hover around 1.5 percent this year, lower than the 2 percent recorded in 2012.
S&P specifically cited Highmark’s deal to acquire West Penn Allegheny Health System as a major financial barrier, saying the financially ailing health system “will continue to be a potential draw on Highmark’s financial resources,” according to the report.
More Articles on West Penn Allegheny Health System and Highmark:
Moody’s to Scrutinize Highmark’s Credit Following West Penn Debt Deal
West Penn-Highmark Transaction Costs to Surpass $1.6B
Highmark Asks Court to Order UPMC to Return Confidential Documents
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
